{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-099485","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.127172+00:00","generated_at":"2026-06-10T21:36:11.315751+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Marker Therapeutics reports complete response in first lymphoma patient treated with MT-601 after CAR T relapse","bullets":["First APOLLO trial patient with DLBCL, after 4 prior therapies including CAR T, achieved complete metabolic response at 8 weeks post 2nd MT-601 infusion.","MT-601 dosed at 200 million cells without prior lymphodepletion; no treatment-related adverse events above Grade 1.","Up to 60% of CAR T patients relapse within one year, underscoring potential of MT-601 in this setting.","Phase 1 APOLLO trial continues to enroll additional participants to evaluate safety and efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-099485","json":"https://secwatch.observer/filing/0001104659-23-099485.json","markdown":"https://secwatch.observer/filing/0001104659-23-099485.md","text":"https://secwatch.observer/filing/0001104659-23-099485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923099485/0001104659-23-099485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923099485/tm2325824d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:36:11.315751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}